The VanEck Pharmaceutical ETF (NASDAQ:PPH) is an investment fund that typically allocates at least 80% of its total assets to securities that make up its benchmark index. This index is comprised of common stocks and depositary receipts of companies listed on U.S. exchanges, specifically those operating in the pharmaceutical industry.
The fund's portfolio may include medium-capitalization companies, which are businesses with a market capitalization between $2 billion and $10 billion, as well as foreign companies that are listed on a U.S. exchange. This allows investors to gain exposure to a diverse range of pharmaceutical companies, from established players to smaller, innovative firms.
As a non-diversified fund, the VanEck Pharmaceutical ETF may invest a larger portion of its assets in a smaller number of securities, which can increase its potential for growth but also raises its risk profile. This fund is designed for investors seeking to tap into the pharmaceutical industry, which is driven by advances in medical research, growing demand for healthcare services, and the development of new treatments and medications.
VanEck, the fund's issuer, is a U.S.-based investment management company with a strong track record of creating ETFs that provide investors with targeted exposure to specific industries and asset classes. You can learn more about the fund and its issuer by visiting their website at http://www.vaneck.com.
The fund is domiciled in the United States, which means it is subject to U.S. regulations and laws governing investment funds. This provides an added layer of oversight and protection for investors.